Corcept Therapeutics Inc., of Menlo Park, Calif., said it recognized $7.3 million in net revenue for the third quarter of 2014 compared to $5.9 million in the second quarter. Revenue increased 177 percent over the prior year comparable period on continued uptake of Korlym for the treatment of Cushing's syndrome.